Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

8.21
-0.1200-1.44%
Post-market: 8.10-0.1100-1.34%18:42 EDT
Volume:1.45M
Turnover:11.86M
Market Cap:460.87M
PE:-105.80
High:8.37
Open:8.29
Low:8.05
Close:8.33
52wk High:13.16
52wk Low:6.19
Shares:56.14M
Float Shares:47.46M
Volume Ratio:1.31
T/O Rate:3.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0776
EPS(LYR):-2.2813
ROE:3.53%
ROA:-18.85%
PB:3.93
PE(LYR):-3.60

Loading ...

Zevra Therapeutics: Positive Data and European Expansion Drive Buy Rating

TIPRANKS
·
Sep 05

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

GlobeNewswire
·
Sep 04

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

GlobeNewswire
·
Aug 28

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

GlobeNewswire
·
Aug 26

Director John B. Bode Reports Acquisition of Common Shares in Zevra Therapeutics Inc

Reuters
·
Aug 21

Crude Oil Down 1%; Performance Food Group Earnings Top Views

Benzinga
·
Aug 14

Zevra Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk

Dow Jones
·
Aug 14

Zevra Therapeutics Is Maintained at Market Outperform by JMP Securities

Dow Jones
·
Aug 13

Stock Track | Zevra Therapeutics Plummets 12.76% Following Mixed Q2 Earnings Report

Stock Track
·
Aug 13

Stock Track | Zevra Therapeutics Plummets 12.76% Pre-market on Earnings Miss Despite Revenue Beat

Stock Track
·
Aug 13

Stock Track | Zevra Therapeutics Plunges 10.80% Pre-market Following Mixed Q2 Earnings Report

Stock Track
·
Aug 13

Zevra Therapeutics Q2 EPS $1.24 Beats $1.13 Estimate, Sales $25.90M Beat $22.49M Estimate

Benzinga
·
Aug 13

Zevra Therapeutics Inc expected to post earnings of $1.50 a share - Earnings Preview

Reuters
·
Aug 09

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire
·
Aug 06

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

GlobeNewswire
·
Aug 04